2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefitsPatient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy
Quick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause The Journal Of The North American Menopause Society 2021, 28: 642-649. PMID: 33534429, DOI: 10.1097/gme.0000000000001738.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCancer SurvivorsCarbon DioxideFemaleFemale Urogenital DiseasesHumansLaser TherapyLasers, GasMenopausePatient Reported Outcome MeasuresPilot ProjectsSyndromeConceptsFemale Sexual Function IndexBC survivorsSexual functionSingle-arm feasibility studyFemale Sexual Distress ScaleOverall FSFI scoreSymptoms of GSMBreast cancer survivorsPatient-reported outcomesSexual Function IndexFractional CO2 laser therapySexual Distress ScaleCO2 laser therapyFSDS-R scoresFractional CO2 laserFSFI scoreAdverse eventsGenitourinary syndromePatient demographicsVaginal drynessCancer survivorsDisease characteristicsFunction IndexLaser therapyDistress Scale
2017
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchMeSH KeywordsAgedBreast NeoplasmsBridged-Ring CompoundsFemaleGaitHumansMaleMiddle AgedNeoplasm StagingPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPostural BalanceSelf ReportTaxoidsTreatment OutcomeConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing